T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with participation from other new investors including, LSP, Qatar Investment Authority (QIA), Casdin Capital, […]
Read MoreAutor: Firma T-knife
T-knife Therapeutics Announces the Appointment of Megan Baierlein as Chief Operating Officer
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the appointment of Megan Baierlein as chief operating officer. “We are excited to welcome Megan to our executive leadership team,” stated Thomas M. Soloway, chief executive officer of T-knife. “Megan has over two decades of […]
Read More